Drug Trial Radar · NCT07653685
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
71
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Conditions
- Colorectal Cancer
Interventions
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injectionDrug
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis.
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)Drug
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 DoseTime frame: Baseline up to 21 days
- Adverse event (AE)Time frame: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
- Objective Response RateTime frame: Baseline up to 24 months
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
Gansu Provincial Tumor Hospital
Lanzhou, Gansu, China · Not yet recruiting
The First People's Hospital of Foshan
Foshan, Guangdong, China · Not yet recruiting
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangxi Zhuang Autonomous Region Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Qiqihar First Hospital
Qiqihar, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, China · Not yet recruiting
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan, China · Not yet recruiting
Jingzhou First People's Hospital
Jingzhou, Hubei, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Provincial Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China · Recruiting
Jiangxi Provincal People's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, China · Not yet recruiting
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, China · Not yet recruiting
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, China · Not yet recruiting
Tianjin Union Medical Center
Tianjin, Tianjin Municipality, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang, China · Not yet recruiting
Lishui Municipal Central Hospital
Lishui, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.